MA33090B1 - Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer - Google Patents
Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au ferInfo
- Publication number
- MA33090B1 MA33090B1 MA34119A MA34119A MA33090B1 MA 33090 B1 MA33090 B1 MA 33090B1 MA 34119 A MA34119 A MA 34119A MA 34119 A MA34119 A MA 34119A MA 33090 B1 MA33090 B1 MA 33090B1
- Authority
- MA
- Morocco
- Prior art keywords
- iron
- deferiprone
- prevention
- treatment
- eye disorders
- Prior art date
Links
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 title abstract 5
- 229960003266 deferiprone Drugs 0.000 title abstract 5
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 8
- 229910052742 iron Inorganic materials 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention porte sur l'utilisation de défériprone disponible par voie orale ou appliquée par voie topique pour la prévention d'un dommage oculaire induit par le fer. L'utilisation peut avoir pour but la préparation d'un médicament ou un procédé consistant à empêcher un dommage oculaire lié au fer à un Sil d'un sujet à risque ce qui concerne un dommage oculaire induit par le fer, le procédé comprenant l'administration d'une quantité prophylactiquement efficace de défériprone au sujet. L'invention porte également sur l'utilisation de défériprone pour le traitement de troubles oculaires liés au fer. L'utilisation peut avoir pour but la préparation d'un médicament ou un procédé de traitement d'un dommage à un Sil souffrant d'un dommage oculaire associé au fer, le procédé comprenant l'administration topique d'une quantité thérapeutiquement efficace de défériprone au sujet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14724509P | 2009-01-26 | 2009-01-26 | |
| PCT/CA2009/001639 WO2010083582A1 (fr) | 2009-01-26 | 2009-11-12 | Utilisation de défériprone pour le traitement et la prévention de troubles oculaires liés au fer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33090B1 true MA33090B1 (fr) | 2012-03-01 |
Family
ID=42355449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34119A MA33090B1 (fr) | 2009-01-26 | 2009-11-12 | Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130023569A1 (fr) |
| EP (1) | EP2389179A4 (fr) |
| JP (1) | JP5604631B2 (fr) |
| KR (1) | KR20120078667A (fr) |
| CN (1) | CN102348456A (fr) |
| AP (1) | AP2011005843A0 (fr) |
| AU (1) | AU2009338093B2 (fr) |
| BR (1) | BRPI0920492A2 (fr) |
| CA (1) | CA2750599A1 (fr) |
| CL (1) | CL2011001812A1 (fr) |
| CR (1) | CR20110456A (fr) |
| EA (1) | EA201170970A1 (fr) |
| IL (1) | IL214291A (fr) |
| MA (1) | MA33090B1 (fr) |
| MX (1) | MX2011007947A (fr) |
| MY (1) | MY161269A (fr) |
| NI (1) | NI201100148A (fr) |
| NZ (1) | NZ594728A (fr) |
| PE (1) | PE20120515A1 (fr) |
| SG (1) | SG173145A1 (fr) |
| TN (1) | TN2011000366A1 (fr) |
| UA (1) | UA103366C2 (fr) |
| WO (1) | WO2010083582A1 (fr) |
| ZA (1) | ZA201105514B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016205030B2 (en) | 2015-01-09 | 2021-04-01 | The Board Of Trustees Of The University Of Illinois | Restoring physiology in iron-deficient organisms using small molecules |
| SG11202003153TA (en) | 2017-10-25 | 2020-05-28 | Chiesi Farm Spa | Delayed release deferiprone tablets and methods of using the same |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| AUPQ262499A0 (en) * | 1999-09-02 | 1999-09-23 | University Of Queensland, The | Novel iron chelators |
| JP4757024B2 (ja) * | 2002-11-07 | 2011-08-24 | テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド | 神経保護鉄キレート剤及びそれを含む医薬組成物 |
| EP1601367A2 (fr) * | 2003-02-06 | 2005-12-07 | Bioresponse L.L.C. | Utilisation combinee d'indoles cruciferes et de chelateurs pour le traitement d'etats lies au papillomavirus |
| BRPI0708211A2 (pt) | 2006-02-22 | 2011-05-17 | Arnold Munnich | o uso de dferiprona e método para tratar e/ou prevenir ataxia de friedreich resultante de mau tratamento intracelular de ferro |
| ZA200809493B (en) | 2006-04-14 | 2010-08-25 | Prana Biotechnology Ltd | Method of treatment of age-related macular degeneration (AMD) |
| ITMI20061770A1 (it) * | 2006-09-18 | 2008-03-19 | Carlo Ghisalberti | Metodo cosmetico di riduzione delle occhiaie |
| US8501789B2 (en) * | 2007-01-19 | 2013-08-06 | The Trustees Of The University Of Pennsylvania | Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease |
-
2009
- 2009-11-12 UA UAA201110546A patent/UA103366C2/ru unknown
- 2009-11-12 MX MX2011007947A patent/MX2011007947A/es not_active Application Discontinuation
- 2009-11-12 CN CN2009801579837A patent/CN102348456A/zh active Pending
- 2009-11-12 EP EP09838587A patent/EP2389179A4/fr not_active Withdrawn
- 2009-11-12 EA EA201170970A patent/EA201170970A1/ru unknown
- 2009-11-12 US US13/138,263 patent/US20130023569A1/en not_active Abandoned
- 2009-11-12 AU AU2009338093A patent/AU2009338093B2/en not_active Ceased
- 2009-11-12 MY MYPI2011003478A patent/MY161269A/en unknown
- 2009-11-12 NZ NZ594728A patent/NZ594728A/xx unknown
- 2009-11-12 AP AP2011005843A patent/AP2011005843A0/xx unknown
- 2009-11-12 KR KR1020117019874A patent/KR20120078667A/ko not_active Withdrawn
- 2009-11-12 MA MA34119A patent/MA33090B1/fr unknown
- 2009-11-12 PE PE2011001408A patent/PE20120515A1/es not_active Application Discontinuation
- 2009-11-12 CA CA2750599A patent/CA2750599A1/fr not_active Abandoned
- 2009-11-12 BR BRPI0920492A patent/BRPI0920492A2/pt not_active IP Right Cessation
- 2009-11-12 JP JP2011546542A patent/JP5604631B2/ja not_active Expired - Fee Related
- 2009-11-12 SG SG2011053972A patent/SG173145A1/en unknown
- 2009-11-12 WO PCT/CA2009/001639 patent/WO2010083582A1/fr not_active Ceased
-
2011
- 2011-07-26 CL CL2011001812A patent/CL2011001812A1/es unknown
- 2011-07-26 TN TN2011000366A patent/TN2011000366A1/fr unknown
- 2011-07-26 NI NI201100148A patent/NI201100148A/es unknown
- 2011-07-26 IL IL214291A patent/IL214291A/en not_active IP Right Cessation
- 2011-07-26 ZA ZA2011/05514A patent/ZA201105514B/en unknown
- 2011-08-24 CR CR20110456A patent/CR20110456A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2011005843A0 (en) | 2011-08-31 |
| CN102348456A (zh) | 2012-02-08 |
| EA201170970A1 (ru) | 2012-03-30 |
| PE20120515A1 (es) | 2012-05-20 |
| AU2009338093A1 (en) | 2011-09-08 |
| US20130023569A1 (en) | 2013-01-24 |
| NZ594728A (en) | 2013-03-28 |
| NI201100148A (es) | 2012-03-06 |
| AU2009338093B2 (en) | 2014-08-28 |
| CA2750599A1 (fr) | 2010-07-29 |
| JP2012515725A (ja) | 2012-07-12 |
| ZA201105514B (en) | 2012-10-31 |
| BRPI0920492A2 (pt) | 2019-07-09 |
| MY161269A (en) | 2017-04-14 |
| TN2011000366A1 (en) | 2013-03-27 |
| MX2011007947A (es) | 2011-12-14 |
| IL214291A0 (en) | 2011-09-27 |
| CR20110456A (es) | 2012-05-31 |
| UA103366C2 (ru) | 2013-10-10 |
| EP2389179A4 (fr) | 2012-08-29 |
| KR20120078667A (ko) | 2012-07-10 |
| CL2011001812A1 (es) | 2012-02-03 |
| IL214291A (en) | 2015-03-31 |
| EP2389179A1 (fr) | 2011-11-30 |
| JP5604631B2 (ja) | 2014-10-08 |
| SG173145A1 (en) | 2011-08-29 |
| WO2010083582A1 (fr) | 2010-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57825B1 (fr) | Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques | |
| MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
| MA44764A (fr) | Méthodes de traitement de patients présentant une hypercholestérolémie familiale | |
| EP2331095A4 (fr) | Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA46430B1 (fr) | Thérapie combinée d'agonistes de cnp à libération contrôlée | |
| FR3065371B1 (fr) | Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2011047439A8 (fr) | Nouvelle thérapie antiparasitaire | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA33090B1 (fr) | Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer | |
| ATE554770T1 (de) | Therapeutisches mittel gegen entzündliche darmerkrankungen | |
| WO2006098603A3 (fr) | Composition renfermant de l'isoorientine pour suppression d'histamine | |
| MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
| MA34106B1 (fr) | Combinaison de composés organiques | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque | |
| WO2009131850A3 (fr) | Inhibiteurs de l’expression et de l’activité de pai-1 pour le traitement des troubles oculaires | |
| FI4048249T3 (fi) | Menetelmiä autismikirjon häiriön oireiden hoitamiseksi | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| EP4138841A4 (fr) | Formulation pour le traitement d'affections ophtalmiques | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| WO2003103699A8 (fr) | Utilisation de ramoplanine pour traiter des troubles associes a la prise d'antibiotiques | |
| WO2018220444A3 (fr) | Compositions et procédés de traitement du syndrome de la kératoconjonctivite sèche par administration d'un antibiotique macrolide | |
| MA33455B1 (fr) | Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux |